Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG)

被引：0
|
作者：
Diehl, Volker
Haverkamp, Heinz [1 ]
Mueller, Rolf Peter [2 ]
Eich, Hans Theodor [2 ]
Mueller-Hermelink, Hans Konrad [3 ]
Cerny, Thomas [4 ]
Markova, Jana [5 ]
Ho, Anthony [6 ]
Kanz, Lothar [7 ]
Greil, Richard [8 ]
Hiddemann, Wolfgang [9 ]
Engert, Andreas [2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, GHSG, Cologne, Germany
[2] Univ Cologne, Dept Radiotherapy, Cologne, Germany
[3] Univ Wurzburg, Dept Pathol, Wurzburg, Germany
[4] Kanionsspital St Gallen, Dept Oncol, St Gallen, Switzerland
[5] Fak Nemocnice, Clin Hematol, Prague, Czech Republic
[6] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany
[7] Univ Tubingen, D-72074 Tubingen, Germany
[8] Salzburg Univ, Dept Internal Med 3, A-5020 Salzburg, Austria
[9] Univ Munic, Dept Internal Med 3, Munic, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：552 / 553
页数：2
相关论文
共 50 条
  • [21] Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
    Engert, Andreas
    Borchmann, Peter
    Pluetschow, Annette
    von Tresckow, Bastian
    Markova, Jana
    Hitz, Felicitas
    Kral, Zdenek
    Greil, Richard
    Topp, Max S.
    Villalobos, Matthias
    Zijlstra, Josee M.
    Soekler, Martin
    Stein, Harald
    Eich, Hans-Theodor
    Mueller, Rolf-Peter
    Fuchs, Michael
    Diehl, Volker
    BLOOD, 2010, 116 (21) : 336 - 336
  • [22] No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG).
    Behringer, Karolin
    Wildt, Ludwig
    Mueller, Horst
    Ott, Helmut-Werner
    Hofer, Susanne
    Diehl, Volker
    van den Hoonard, Beate
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2009, 114 (22) : 1429 - 1429
  • [23] PET scan after four cycles of BEACOPP in therapy of advanced stage of Hodgkin S lymphoma (treated within HD15 study of German Hodgkin lymphoma study group)
    Markova, J.
    Klaskova, K.
    Polivka, J.
    Zikavska, L.
    Foglova, M.
    Hynkova, L.
    Vernerova, Z.
    Skopalova, M.
    Belohlavek, O.
    Dedeckova, K.
    Campr, V.
    Kamaradova, K.
    Kozak, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 71 - 71
  • [24] ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
    Mounier, N.
    Brice, P.
    Bologna, S.
    Briere, J.
    Gaillard, I.
    Heczko, M.
    Gabarre, J.
    Casasnovas, O.
    Jaubert, J.
    Colin, P.
    Delmer, A.
    Devidas, A.
    Bachy, E.
    Nicolas-Virelizier, E.
    Aoudjhane, A.
    Humbrecht, C.
    Andre, M.
    Carde, P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1622 - 1628
  • [25] ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.
    Carde, Patrice P.
    Karrasch, Matthias
    Fortpied, Catherine
    Brice, Pauline
    Khaled, Hussein Mustafa
    Caillot, Denis
    Gaillard, Isabelle
    Bologna, Serge
    Ferme, Christophe
    Lugtenburg, Pieternella
    Morschhauser, Franck
    Aurer, Igor
    Coiffier, Bertrand
    Cantin, Guy
    Seftel, Matthew D.
    Wolf, Max
    Glimelius, Bengt
    Sureda, Anna
    Mounier, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Response assessment after 4 cycles of beacopp using FDG-PET in patients with advanced-stage hodgkin lymphoma
    Markova, J.
    Kahraman, T. D.
    Kobe, C.
    Skopalova, M.
    Dedeckova, K.
    Gaherova, L.
    Dietlein, M.
    Kozak, T.
    ONKOLOGIE, 2011, 34 : 132 - 132
  • [27] RESPONSE ASSESSMENT AFTER 4 CYCLES OF BEACOPP USING FDG-PET IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA
    Markova, J.
    Kobe, C.
    Skopalova, M.
    Dedeckova, K.
    Mocikova, H.
    Klaskova, K.
    Kahraman, D.
    Dietlein, M.
    Kozak, T.
    ANNALS OF ONCOLOGY, 2011, 22 : 160 - 160
  • [28] BEACOPP chemotherapy in elderly patients with advanced Hodgkin's disease: Analysis of the randomized trial HD9 for elderly patients of the German Hodgkin lymphoma study group (GHSG).
    Ballova, V
    Franklin, J
    Josting, A
    Wolf, J
    Diehl, V
    Engert, A
    BLOOD, 2003, 102 (11) : 400A - 400A
  • [29] Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials
    Haverkamp, Heinz
    Boell, Boris
    Eichenauer, Dennis A.
    Sasse, Stephanie
    Fuchs, Michael
    Borchmann, Peter
    Diehl, Volker
    Engert, Andreas
    von Tresckow, Bastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) : 2430 - U35
  • [30] PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
    Eichenauer, D. A.
    Kreissl, S.
    Buehnen, I.
    Goergen, H.
    Hartmann, S.
    Fuchs, M.
    von Tresckow, B.
    Engert, A.
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 87 - 88
12345